Illumina, Inc. (ILMN) recently acquired Fluent BioSciences, a developer of innovative single-cell technology. This strategic acquisition marks a significant step in Illumina's expansion within the single-cell research domain, aligning with the company’s broader multiomics growth strategy.The acquisition was completed on Jul 9 and funded with cash on hand. However, other financial terms of the deal were not disclosed.Enhancing Single-Cell Research CapabilitiesFluent BioSciences has developed a highly differe ...

Core Insights - The acquisition of Fluent BioSciences by Illumina enhances Illumina's capabilities in single-cell research, a key growth area, and supports its multiomics growth strategy [1][2] - Fluent's single-cell analysis technology simplifies the process by eliminating the need for complex and costly instrumentation, making it more accessible to a wider range of customers [1] - The integration of Fluent's PIPseq™ V technology into Illumina's product portfolio aims to provide comprehensive solutions for single-cell analysis, enabling faster and more economical research [2] Company Overview - Illumina is a global leader in DNA sequencing and array-based technologies, focusing on innovation to improve human health through genomic insights [4] - The company serves various markets, including life sciences, oncology, reproductive health, and agriculture, with a commitment to maintaining an open NGS platform and supporting existing single-cell partnerships [2][4] Technology and Product Development - Fluent's PIPseq V technology offers high scalability, capable of processing from 100 cells to 1 million, and excels in detecting cell types often missed by current methods [1] - The acquisition, which closed on July 9, 2024, was funded with cash on hand, indicating a strategic investment in enhancing Illumina's product offerings [2]

Key TakeawaysIllumina said it would take a $1.47 billion goodwill impairment charge related to its spinoff of cancer testing company GRAIL.Illumina also said it would take a $420 million charge for GRAIL's in-process R&D.Illumina's purchase of GRAIL prior to regulatory approval had been steeped in controversy for years. The breakup with GRAIL (GRAL) was costly for Illumina (ILMN). The gene sequencing company wrote in a regulatory filing Thursday that it would take a $1.47 billion goodwill impairment charge ...

Tatsiana Volkava/iStock via Getty Images Investment Overview - Illumina Says Goodbye To GRAIL, & It's Worst Ever Business Decision This week, Illumina (NASDAQ:ILMN), the San Diego, California-based gene sequencing giant, brought an end to a disastrous chapter in its relatively short history by completing the divestiture of GRAIL, the cancer testing business it helped to found. The GRAIL saga has run and run, and ultimately, played a significant role in destroying the value of Illumina stock. As I wrote in a ...

(Photo credit should read CFOTO/Future Publishing via Getty Images)Future Publishing via Getty ImagesOn June 25, 2024, Illumina, Inc. (NASDAQ: ILMN, $208.92, Market Capitalization: $18.51 billion) announced the completion of the tax free spin-off of GRAIL, Inc. (NASDAQ: GRAL, $36.84, Market Capitalization: $3.26 billion). On June 25, 2024, both the stocks started regular way trading with, new Illumina opening at $108.24, making an intraday high of $112.49, low of $106.26 and closed at $109.84. On the other ...

Following three years of nonstop regulatory hassles, Illumina (ILMN) finally gave up on GRAIL, leading to the successful completion of its spin-off yesterday. Following the announcement, shares of Illumina rose 1.5% at yesterday’s close and also edged up 0.1% during the after-hour trading session.With the divestment now complete, GRAIL will start trading publicly on Nasdaq from Jun 25 under the ticker symbol "GRAL." Illumina will continue to operate its legacy business independently under the ticker symbol ...

The world of biotech stocks got a new member today. Grail (NASDAQ:GRAL) has successfully completed its spinoff from industry leader Illumina (NASDAQ:ILMN). Previously, Grail had functioned as the company’s cancer-testing unit. However, after regulatory pressure, Illumina, known for its advances in the field of DNA sequencing, opted for the spinoff that would allow Grail to function as its own separate entity. Today, GRAL stock begins trading on the Nasdaq in what could be one of the summer’s hottest market ...

GRAIL spin-off complete; GRAIL to begin regular way trading as "GRAL" on June 25Illumina to issue second quarter 2024 results on August 6; leadership to present Strategy Update on August 13SAN DIEGO, June 24, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the successful completion of the spin-off of GRAIL. This milestone follows the company's previously announced plans to divest GRAIL, and GRAIL is now a public and independent company. GRAIL will begin regular way trading on Nasdaq on Tu ...

Illumina, Inc. (ILMN) has progressed in genomic research with the recent launch of DRAGEN v4.3. This is the latest version of the company’s DRAGEN software line.This new release marks a significant advancement in the field of next-generation sequencing (NGS), featuring an advanced multigenome mapping technology. This innovation allows for the inclusion of 128 samples from 26 different ancestries, thus capturing a broader spectrum of genetic diversity and reducing ancestry bias.The ability to create custom D ...

(Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesOn June 3, 2024, Illumina’s (NASDAQ: ILMN, $109.82, Market Capitalization: $17.5 billion) board of directors approved the spin-off of its wholly owned subsidiary GRAIL, Inc. and shared the details on the timeline.Earlier on May 6, 2024, ILMN had filed the initial Form 10 disclosing the deal overview and separation agreement. Subsequently, on June 3, 2024, ILMN submitted an amended Form 10 d ...